Research Peptide Bali

Peptide science, referenced

A plain-language, referenced guide to peptide research

What the trials actually measured, what regulators approved and where, and how research peptides are tested. Every article is written from primary sources and lists them in full, with the figures drawn from the published data.

All articles 7

GLP-1 / GIP medicine

Tirzepatide: The Trials Behind the Approvals

How tirzepatide was designed, what the SURPASS and SURMOUNT trials measured, where regulators approved it, and the warnings printed on its label.

2026-09-17 · 15 min read

GLP-1 medicine

Semaglutide: SUSTAIN-6, STEP 1, SELECT and FLOW Explained

How semaglutide was designed for a weekly schedule, what four landmark trials measured, how its approvals grew, and the safety signals on its label.

2026-09-17 · 9 min read

Investigational

Retatrutide: Phase 3 Results and What Is Still Unknown

Retatrutide acts on three hormone receptors and is still investigational. What its phase 2 trial and the TRIUMPH phase 3 trials have reported so far.

2026-09-17 · 7 min read

Explainer

GLP-1 and GIP: The Gut Hormones Behind the New Medicines

What GLP-1 and GIP do in the body, why the natural hormones cannot be used as medicines, and how chemists made them last a week. A sourced history.

2026-09-17 · 7 min read

Research peptide

BPC-157: What the Published Evidence Contains

BPC-157 is widely discussed and approved nowhere. An inventory of its research: animal studies, three small human reports, and what regulators say.

2026-09-17 · 7 min read

Peptide medicine

Tesamorelin: A Peptide Approved for One Narrow Use

Tesamorelin is an approved analogue of growth hormone releasing factor with a single, narrow indication. Its trials, the limits on its label, and its warnings.

2026-09-17 · 6 min read

Explainer

How a Peptide Becomes an Approved Medicine

The path from laboratory to label: animal studies, three phases of human trials, review by the FDA and BPOM, and what an approval does and does not cover.

2026-09-17 · 9 min read